Envoy Medical Inc (NASDAQ: COCH) is a medical device company developing the Acclaim cochlear implant (Acclaim CI), a fully implanted hearing device seeking FDA approval. The company has not generated commercial revenue as of its 10-K filed March 23, 2026, and funds operations through equity and debt capital raises. Envoy Medical reported a net loss of $23,756 thousand for the year ended December 31, 2025, with cash used in operating activities driven primarily by that net loss. The company raised approximately $27,730 thousand in net proceeds from a February 2026 equity offering, with warrants structured around FDA submission and approval milestones for the Acclaim CI. Reimbursement from Medicare, Medicaid, and private insurers is identified as essential to any future commercial viability. The company operates under a building lease with Taylor Corporation and a services agreement with Taylor Technology Services, both related-party arrangements.

Revenue model

Envoy Medical has no disclosed commercial revenue as of the 10-K filed March 23, 2026. The company funds operations through equity offerings, including an at-the-market facility with Roth Capital Partners established January 17, 2025, and debt instruments such as a promissory note with GAT Funding. Future revenue, if any, would depend on FDA approval and third-party payor reimbursement for the Acclaim CI.

Products and services

The Acclaim CI is the company's sole disclosed product in development. It is a cochlear implant seeking FDA premarket approval (PMA). The device is in the clinical trial and development stage as of the 10-K filed March 23, 2026, with no commercial sales disclosed.

Customers and end markets

Target end market is patients with hearing loss requiring cochlear implantation. Reimbursement from Medicare, Medicaid, and private health insurers is identified as essential for patient access. No commercial customers are disclosed as of the 10-K filed March 23, 2026.

Value-chain role

Envoy Medical is a device developer and manufacturer-in-development, sourcing components from third-party suppliers and contracting external vendors for research and clinical trial services. The company is not yet a major customer of its suppliers, which the filing identifies as a supply chain risk.

Geographic exposure

The filing references potential reimbursement and regulatory considerations in the United States and the European Union, but no commercial geographic revenue mix is disclosed as of the 10-K filed March 23, 2026.

Source: SEC 10-K, filed 2026-03-23

Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies Peers: Abbott Laboratories CUTERA INC Aspira Women's Health Inc USBC Inc Co-Diagnostics Inc Daxor Corp IRIDEX Corp NeuroOne Medical Technologies Corp Owlet Inc